Clinical Trial Update: Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of inhaled prostaglandin E1 for hypoxemic respiratory failure in premature infants was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prematurity
• Pulmonary Hypertension
• Respiratory Distress Syndrome Newborn
• Respiratory Insufficiency

Drugs mentioned

• Inhaled Prostaglandin E1 (Prostaglandin E1 (IPGE1))

Snippet

Sponsor: NICHD Neonatal Research Network | Conditions: Prematurity, Respiratory Insufficiency | Phase 2 | Status: TERMINATED | Results posted: 2016-12-30